Thyroid Eye Disease (TED) Clinical Trials

RECRUITING: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease.
https://clinicaltrials.gov/study/NCT06248619?term=NCT06248619&rank=1

TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED). The first international approval outside of the U.S.

FDA expands teprotumumab indication to include any thyroid eye disease duration, activity.

Research presented  at the American Society of Ophthalmic, Plastic, and Reconstructive Surgery annual meeting noted a decrease in eye muscle size for patients with TED who underwent treatment with TEPEZZA (TM), resulting in better eye movement and less double vision.

Clinical Trial – A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease (UplighTED)
Condition – Thyroid Eye Disease
Official Title – A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants with Thyroid Eye Disease
Intervention – Combination Product: Efgartigimod PH20SC and Placebo
Delivery – subcutaneous injection
Total Number of treatments – 24 weeks; Open-Label Extension study available
Time between treatments – 1 week
Recruiting – Now
Recruiting – 108 participants
NCT Number: NCT06307626
EU Trial (CTIS) Number: 2023-509198-22-00
Study Name: UplighTED – ARGX – 113-2301; ARGX – 113-2309

ACELYRIN is currently recruiting for a clinical study designed to evaluate lonigutamab in subjects with TED. Use this link to learn more.

Genentech is currently enrolling for their TED research study and are inviting interested patients to check their eligibility. The investigational treatment is a subcutaneous injection that aims to provide relief for symptoms of TED like eye bulging and double vision.

• STRIVE 
  • Phase 3, Randomized, Controlled, Safety and Tolerability Study of VRDN-001 for people with active or chronic TED
  • Ct.gov https://clinicaltrials.gov/study/NCT06384547
  • Recruiting
• REVEAL-1
  • Global phase 3 clinical trial studying a potential treatment, VRDN-003 given by subcutaneous injection, for people affected by active TED
  • https://clinicaltrials.gov/study/NCT06625411
  • Recruiting participants
• REVEAL-2
  • Global a phase 3 clinical trial studying a potential treatment, VRDN-003 given by subcutaneous injection, for people affected by chronic TED
  • https://clinicaltrials.gov/study/NCT06625398
  • Recruiting participants

Tourmaline Bio is currently enrolling in the spiriTED Study – A Phase 2b clinical study investigating study drug TOUR-006 in patients with TED. Please visit – https://clinicaltrials.gov/study/NCT06088979 or https://lpcur.com/TEDCommunityOrganization for more information.

Immunovant is presently recruiting for a TED clinical research study. Please use this link to learn more.

See “Understanding Thyroid Eye Disease” contributed by Immunovant.

Sling Therapeutics is now recruiting participants for a Phase 2b study to evaluate a new oral treatment for TED.

Lassen Therapeutics is currently recruiting for 2 clinical trials evaluating a novel treatment for people with TED.

LASN01-CL-2201
Phase 2 clinical trial exploring LASN01 as a potential treatment for people with active TED
https://clinicaltrials.gov/study/NCT06226545?term=lasn01&rank=1

LASN01-CL-1101
Phase 1 clinical trial further exploring LASN01 in people with active TED or idiopathic pulmonary fibrosis (IPF)
https://clinicaltrials.gov/study/NCT05331300?term=lasn01&rank=2